H. Bailey

发表

The Continual Reassessment Method for Multiple Toxicity Grades: A Bayesian Quasi‐Likelihood Approach

R. Chappell, Z. Yuan, H. Bailey, 2007, Biometrics.

Constitutive and β-Naphthoflavone-induced Expression of the Human γ-Glutamylcysteine Synthetase Heavy Subunit Gene Is Regulated by a Distal Antioxidant Response Element/TRE Sequence*

R. Mulcahy, H. Bailey, M. Wartman, 1997, The Journal of Biological Chemistry.

Pilot study of intravenous melphalan combined with continuous infusion L‐S,R‐buthionine sulfoximine for children with recurrent neuroblastoma

S. Groshen, J. Maris, K. Matthay, 2015, Pediatric blood & cancer.

Buthionine Sulfoximine and Myeloablative Concentrations of Melphalan Overcome Resistance in a Melphalan-Resistant Neuroblastoma Cell Line

R. Seeger, N. Satake, C. Reynolds, 2001, Journal of pediatric hematology/oncology.

A randomized, double-blind, dose-ranging, pilot trial of piperine with resveratrol on the effects on serum levels of resveratrol.

KyungMann Kim, N. Ahmad, J. Johnson, 2020, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

Human metabolism of the experimental cancer therapeutic agentd-limonene

M. Gould, C. Elson, J. Haag, 2004, Cancer Chemotherapy and Pharmacology.

Recruitment Strategies for Cancer Prevention Trials

P. Carbone, H. Bailey, K. Sielaff, 2005 .

Cancer chemoprevention is not a failure.

V. Adhami, H. Mukhtar, H. Bailey, 2014, Carcinogenesis.

A phase II randomized placebo‐controlled trial of pomegranate fruit extract in men with localized prostate cancer undergoing active surveillance

H. Parnes, KyungMann Kim, H. Mukhtar, 2020, The Prostate.

Phase II Study of 1α-Hydroxyvitamin D2 in the Treatment of Advanced Androgen-independent Prostate Cancer

G. Wilding, R. Chappell, H. Bailey, 2003 .

Oncologic Implications of Chronic Hepatitis C Virus Infection.

L. Foxhall, E. Sturgis, Janette K Merrill, 2019, Journal of oncology practice.

A phase I study of vorinostat in combination with bortezomib in patients with advanced malignancies

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

A Phase I study of intermittently dosed vorinostat in combination with bortezomib in patients with advanced solid tumors

G. Wilding, J. Kolesar, J. Eickhoff, 2013, Investigational New Drugs.

A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1α,24(S)Dihydroxyvitamin D2) in patients with advanced cancer

G. Wilding, J. Kolesar, K. Wisinski, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A phase 2 study of temsirolimus (CCI‐779) in patients with soft tissue sarcomas

D. Ettinger, J. Sarkaria, M. Mahoney, 2011, Cancer.

Phase I study of continuous MKC-1 in patients with advanced or metastatic solid malignancies using the modified Time-to-Event Continual Reassessment Method (TITE-CRM) dose escalation design

G. Wilding, J. Eickhoff, A. Tevaarwerk, 2012, Investigational New Drugs.

Dose-escalation study of fixed-dose rate gemcitabine combined with capecitabine in advanced solid malignancies

G. Wilding, J. Eickhoff, A. Tevaarwerk, 2009, Cancer Chemotherapy and Pharmacology.

A Randomized, Placebo-Controlled, Double-Blind, Dose Escalation, Single Dose, and Steady-State Pharmacokinetic Study of 9cUAB30 in Healthy Volunteers

H. Parnes, J. Kolesar, KyungMann Kim, 2019, Cancer Prevention Research.

An asterisk indicates reviewers who have evaluated three or more manuscripts in 2012.

David Ball, Ash A. Alizadeh, David A. August, 2013 .

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer

KyungMann Kim, C. Zalles, B. Kimler, 2015, Cancer Prevention Research.

Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer

R. Mazess, G. Wilding, R. Bruskewitz, 2002 .

A phase I trial of intraperitoneal sustained-release paclitaxel microspheres (Paclimer) in recurrent ovarian cancer: a Gynecologic Oncology Group study.

G. Fleming, D. Armstrong, M. Markman, 2006, Gynecologic oncology.

Cloning and sequencing of the cDNA for the light subunit of human liver gamma-glutamylcysteine synthetase and relative mRNA levels for heavy and light subunits in human normal tissues.

R. Mulcahy, H. Bailey, J. Gipp, 1995, Biochemical and biophysical research communications.

Inpatient hospitalization of oncology patients: are we missing an opportunity for end-of-life care?

J. Eickhoff, J. Cleary, T. Campbell, 2013, Journal of oncology practice.

Soy food frequency questionnaire does not correlate with baseline isoflavone levels in patients with bladder cancer

E. Messing, H. Parnes, J. Kolesar, 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

A Phase II Randomized, Double-blind, Presurgical Trial of Polyphenon E in Bladder Cancer Patients to Evaluate Pharmacodynamics and Bladder Tissue Biomarkers

H. Parnes, J. Kolesar, KyungMann Kim, 2017, Cancer Prevention Research.

A phase II trial of daily perillyl alcohol in patients with advanced ovarian cancer: Eastern Cooperative Oncology Group Study E2E96.

S. Wadler, F. Foss, H. Bailey, 2002, Gynecologic oncology.

A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer

R. Buller, M. Shahin, R. Alvarez, 2007 .

Progress of a Comprehensive Familial Cancer Genetic Counseling Program in the Era of BRCA1 and BRCA2.

D. Petereit, R. Laxová, H. Bailey, 2002, Genetic testing.

Predictors of Willingness to Participate in Window-of-Opportunity Breast Trials

KyungMann Kim, J. McElroy, K. Wisinski, 2013, Clinical Medicine & Research.

Phase I trial of perillyl alcohol administered four times daily continuously

G. Wilding, M. Gould, H. Bailey, 2003, Cancer Chemotherapy and Pharmacology.

Phase I trial of perillyl alcohol administered

G. Wilding, M. Gould, H. Bailey, 2003 .

A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors

G. Wilding, J. Eickhoff, W. Schelman, 2008, Cancer Chemotherapy and Pharmacology.

A phase II study of irinotecan (CPT‐11) in patients with advanced squamous cell carcinoma of the cervix

W. Irvin, H. Bailey, R. Potkul, 1998 .

Phase II Study of Weekly Low-Dose Paclitaxel for Relapsed and Refractory Non-Hodgkin's Lymphoma: A Wisconsin Oncology Network Study

KyungMann Kim, H. Bailey, E. Williams, 2005, Cancer investigation.

Transfection of complementary DNAs for the heavy and light subunits of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan.

R. Mulcahy, H. Bailey, J. Gipp, 1995, Cancer research.

Phase I clinical and pharmacokinetic trial of the cyclin-dependent kinase inhibitor flavopiridol

G. Wilding, J. Cleary, H. Bailey, 2002, Cancer Chemotherapy and Pharmacology.

Gemcitabine, Paclitaxel, and Piritrexim: A Phase I Study

G. Wilding, H. Bailey, R. Arzoomanian, 2003, American journal of clinical oncology.

Up-regulation of γ-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels

R. Mulcahy, H. Bailey, J. Gipp, 2004, Cancer Chemotherapy and Pharmacology.

Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione.

G. Wilding, D. Spriggs, R. Mulcahy, 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

R. Mazess, G. Wilding, R. Bruskewitz, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

L-S,R-buthionine sulfoximine: historical development and clinical issues.

H. Bailey, 1998, Chemico-biological interactions.

Epidemiologic Factors and Urogenital Infections Associated With Preterm Birth in a Midwestern U.S. Population

D. Baumgardner, A. Borgert, S. Lovrich, 2014, Obstetrics and gynecology.

Phase II Study of 1-Hydroxyvitamin D 2 in the Treatment of Advanced Androgen-independent Prostate Cancer 1

G. Wilding, R. Chappell, H. Bailey, 2003 .

Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies

G. Wilding, T. Mody, H. Bailey, 2011, Investigational New Drugs.

Vorinostat in combination with bortezomib in patients with advanced malignancies directly alters transcription of target genes

G. Wilding, J. Kolesar, KyungMann Kim, 2013, Cancer Chemotherapy and Pharmacology.

A phase I trial of 5-fluorouracil, leucovorin, and dipyridamole given by concurrent 120-h continuous infusions

G. Wilding, J. Grem, D. Spriggs, 1992, Cancer Chemotherapy and Pharmacology.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days

G. Wilding, R. Hohl, S. Holstein, 2004, Cancer Chemotherapy and Pharmacology.

The differential diagnosis of pulmonary blastomycosis using case vignettes: a Wisconsin Network for Health Research (WiNHR) study.

D. Baumgardner, J. Temte, H. Bailey, 2011, WMJ : official publication of the State Medical Society of Wisconsin.

Enhancing the bioavailability of resveratrol by combining it with piperine.

H. Mukhtar, I. Siddiqui, M. Nihal, 2011, Molecular nutrition & food research.

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Skin Cancer Prevention Study of α-Difluoromethylornithine in Subjects with Previous History of Skin Cancer

M. Pomplun, KyungMann Kim, P. Carbone, 2010, Cancer Prevention Research.

Global Epidemiology, Prevention, and Management of Hepatocellular Carcinoma.

L. Foxhall, E. Sturgis, M. Yuen, 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Phase I Clinical Trial of Fazarabine as a Twenty-four-Hour Continuous Infusion 1

G. Wilding, H. Bailey, K. Tutsch, 2006 .

P. Pfau, J. Sosman, K. Kozak, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome

KyungMann Kim, H. Bailey, B. Kahl, 2008, Leukemia & lymphoma.

Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan.

D. Mahvi, G. Wilding, R. Mulcahy, 1997, Journal of the National Cancer Institute.

Non-Hodgkin's lymphoma presenting as a pelvic mass with elevated CA-125.

S. Howard, H. Bailey, A. Forouzannia, 2004, Gynecologic oncology.

Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network.

C. Jones, J. Zehnder, J. Eickhoff, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase 2 Cancer Chemoprevention Biomarker Trial of Isoflavone G-2535 (Genistein) in Presurgical Bladder Cancer Patients

E. Messing, H. Parnes, J. Kolesar, 2012, Cancer Prevention Research.

A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS).

D. Ettinger, B. Bot, M. Mahoney, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical and pharmacokinetic study of perillyl alcohol administered four times a day.

G. Wilding, M. Gould, H. Bailey, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase I Clinical and Pharmacokinetic Study of Perillyl Alcohol Administered Four Times a Day 1

G. Wilding, M. Gould, H. Bailey, 2000 .

Phase I clinical trial of perillyl alcohol administered daily.

G. Wilding, M. Gould, J. Stewart, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Phase II trial of daily oral perillyl alcohol (NSC 641066) in treatment-refractory metastatic breast cancer

R. Love, J. Stewart, S. Attia, 2008, Cancer Chemotherapy and Pharmacology.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

D. DeMets, G. Wilding, H. Bailey, 2003, Investigational New Drugs.

Green tea polyphenols for prostate cancer chemoprevention: a translational perspective.

H. Mukhtar, J. Johnson, H. Bailey, 2010, Phytomedicine : international journal of phytotherapy and phytopharmacology.

Nirogacestat, a γ-Secretase Inhibitor for Desmoid Tumors.

M. Burgess, R. Riedel, M. Gounder, 2023, The New England journal of medicine.

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology.

Richard L Schilsky, Michael N Neuss, Howard A Fine, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase III Skin Cancer Chemoprevention Study of DFMO: Long-term Follow-up of Skin Cancer Events and Toxicity

Eneida A. Mendonça, KyungMann Kim, E. Mendonça, 2012, Cancer Prevention Research.

Maintenance rituximab following induction chemo-immunotherapy for mantle cell lymphoma: long-term follow-up of a pilot study from the Wisconsin Oncology Network

J. Eickhoff, H. Bailey, B. Kahl, 2011, Leukemia & lymphoma.

American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention.

L. Foxhall, N. Dupont, C. Blanke, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I clinical trial of fazarabine as a twenty-four-hour continuous infusion.

G. Wilding, H. Bailey, K. Tutsch, 1991, Cancer research.

A phase I study of SR-2508 and cyclophosphamide administered by intravenous injection.

G. Wilding, D. Trump, R. Mulcahy, 1991, Cancer research.

Metastatic soft tissue sarcoma diagnosed by small bowel video capsule endoscopy.

S. Weber, D. Gopal, S. Attia, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of daily oral perifosine in patients with advanced soft tissue sarcoma

D. Ettinger, M. Mahoney, P. Fracasso, 2006, Cancer.

Phase I clinical and pharmacokinetic trial of irofulven

G. Wilding, H. Bailey, K. Tutsch, 2001, Cancer Chemotherapy and Pharmacology.

A phase I study of vorinostat in combination with bortezomib in refractory solid tumors.

G. Wilding, J. Kolesar, J. Wright, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Survey of Baseline Tobacco Cessation Clinical Practices and Receptivity to Academic Detailing.

M. Fiore, K. Wisinski, R. Adsit, 2016, WMJ : official publication of the State Medical Society of Wisconsin.

Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy

E. Messing, H. Parnes, J. Kolesar, 2016, European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation.

A phase IIa randomized placebo-controlled trial of pomegranate fruit extract/POMx in subjects with clinically localized prostate cancer undergoing active surveillance.

H. Parnes, KyungMann Kim, H. Mukhtar, 2020 .

Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.

G. Wilding, R. Mulcahy, M. Ripple, 1992, Cancer research.

Phase I Trial of Weekly Paclitaxel and BMS-214662 in Patients with Advanced Solid Tumors

G. Wilding, R. Martell, M. Gottardis, 2007, Clinical Cancer Research.

Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase II trial.

J. Fine, D. Kushner, J. Connor, 2007, Gynecologic oncology.

Phase IIa, randomized placebo-controlled trial of single high dose cholecalciferol (vitamin D3) and daily Genistein (G-2535) versus double placebo in men with early stage prostate cancer undergoing prostatectomy.

H. Parnes, J. Kolesar, KyungMann Kim, 2016, American journal of clinical and experimental urology.

Ototoxicity of Long‐Term α‐Difluoromethylornithine for Skin Cancer Prevention

KyungMann Kim, H. Bailey, T. Havighurst, 2022, The Laryngoscope.

A phase II consortium trial of vorinostat and bortezomib for advanced soft tissue sarcomas.

M. Mahoney, C. Erlichman, W. Maples, 2011, Journal of Clinical Oncology.

Phase II open label, multi‐center clinical trial of modulation of intermediate endpoint biomarkers by 1α‐hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin

G. Wilding, J. Kolesar, W. See, 2013, The Prostate.

A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors

C. Kyriakopoulos, J. Kolesar, J. Eickhoff, 2017, Investigational New Drugs.

Brief report: Measuring the attitudes of health care professionals in Dane County toward adolescent immunization with HPV vaccine.

KyungMann Kim, J. McElroy, H. Bailey, 2009, WMJ : official publication of the State Medical Society of Wisconsin.

Increased expression of gamma-glutamyl transpeptidase in transfected tumor cells and its relationship to drug sensitivity.

R. Mulcahy, H. Bailey, J. Gipp, 1994, Cancer letters.

A phase I safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced solid tumors.

R. Kurzrock, J. Wheler, S. Moulder, 2010 .

Abstract B247: A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced solid tumors

R. Kurzrock, J. Wheler, G. Falchook, 2009 .

The Wisconsin Network for Health Research (WiNHR): a statewide, collaborative, multi-disciplinary, research group.

Ingrid Glurich, D. DeMets, S. Yale, 2009, WMJ : official publication of the State Medical Society of Wisconsin.